Skip to main content
  • Loading metrics

Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity


G protein–coupled receptors (GPCRs) are critical regulators of cellular function acting via heterotrimeric G proteins as their primary transducers with individual GPCRs capable of pleiotropic coupling to multiple G proteins. Structural features governing G protein selectivity and promiscuity are currently unclear. Here, we used cryo-electron microscopy (cryo-EM) to determine structures of the cholecystokinin (CCK) type 1 receptor (CCK1R) bound to the CCK peptide agonist, CCK-8 and 2 distinct transducer proteins, its primary transducer Gq, and the more weakly coupled Gs. As seen with other Gq/11–GPCR complexes, the Gq–α5 helix (αH5) bound to a relatively narrow pocket in the CCK1R core. Surprisingly, the backbone of the CCK1R and volume of the G protein binding pocket were essentially equivalent when Gs was bound, with the Gs αH5 displaying a conformation that arises from “unwinding” of the far carboxyl-terminal residues, compared to canonically Gs coupled receptors. Thus, integrated changes in the conformations of both the receptor and G protein are likely to play critical roles in the promiscuous coupling of individual GPCRs.


G protein–coupled receptors (GPCRs) are ubiquitous regulators of cellular function, acting as allosteric conduits of external signals to generation of integrated cell and organ response [1]. The primary transducers of activated GPCRs are heterotrimeric G proteins, comprised of distinct Gα and Gβγ subunits. While GPCRs are often classified according to the best coupled Gα subunit family, most GPCRs can couple, selectively, to members of multiple G protein subfamilies, and it is increasingly recognised that integrated signalling from multiple G proteins, and other transducers, plays an important role in governing complex cell responses [2,3]. However, the molecular basis for G protein selectivity of GPCRs remains poorly understood, with a major limitation being lack of structures of individual GPCRs bound to different G proteins.

Advances in single-particle cryo-electron microscopy (cryo-EM) have enabled determination of agonist-activated GPCRs in complex with canonical transducer G proteins of the Gs, Gi/o, and Gq/11 families using a range of biochemical approaches for stabilisation of these complexes [48]. However, these have not yet translated to robust generation of complexes of GPCRs bound to more weakly coupled G proteins. A number of mechanisms, in addition to specific receptor–G protein interactions, have been proposed to contribute to G protein selectivity including the volume of the intracellular binding pocket in the receptor and the degree of conformational flexibility in TM6 [9]. In particular, in most structures solved to date, the Gαs protein exhibits a bulkier carboxyl-terminal α5 helix (αH5) arising from a “hook” conformation of the far carboxyl terminus that requires a larger binding pocket in the core of the receptor to be accommodated [6,10]. In these GPCR–Gs complex structures, TM6 is splayed further away from the core than is seen for Gi/o or Gq/11 complexes where these are the primary transducers. However, in more recent class A GPCR–Gs complexes, greater divergence in the conformation of the intracellular TM helix ends has been observed [11,12]. Moreover, in the EP4 receptor, the carboxyl-terminal Gαs “hook” unwinds to enable novel engagement with the receptor [11] that could also enable binding of Gs to receptors that have narrower intracellular cavities when activated. The αH5 of Gi/o or Gq/11 proteins is less bulky, and these proteins can be readily accommodated with smaller outward movement of TM6. It is clear that the nature of G protein engagement with GPCRs is complex and that individual receptor subfamilies can exhibit divergence in modes of G protein engagement, even for equivalent Gα proteins. This also raises questions on the mechanisms that contribute to G protein selectivity/promiscuity for individual GPCRs, which is critical for molecular understanding of biased agonists that can alter the pattern of G protein binding to GPCRs [13].

Recently, we solved structures of the glucagon receptor, a primarily Gs coupled receptor, in complex with Gs or Gi1 proteins, providing the first structural insight into G protein coupling pleiotropy [14]. In contrast to expectation, the receptor backbone and intracellular pocket volume were equivalent regardless of the G protein bound, but with Gi1 binding within this cavity with fewer contacts. Currently, it is unclear how GPCRs, where Gq/11 proteins are the primary transducers, pleiotropically engage with Gs proteins.

The cholecystokinin (CCK) type 1 receptor (CCK1R) is a Gq/11 coupled class A GPCR localised on afferent vagal nerves that mediates the neuroendocrine peptide hormone actions of CCK on regulation of food intake and body weight [1517]. Through effects on gastric emptying and gut transit, in concert with stimulation of gall bladder contraction and pancreatic exocrine secretion, the CCK–CCK1R axis is a key physiologic servomechanism for optimal nutrient delivery and maintenance of body weight. CCK was also the first gut peptide shown to control satiety, and the CCK1R has been pursued as a potential target for treatment of obesity.

While Gq/11 protein–dependent signalling has been the focus of pharmacological characterisation of the CCK1R, like most GPCRs, it is pleiotropically coupled and can initiate signalling via multiple transducers, including Gs- and G13-linked signalling, arrestin recruitment, and a wide array of other downstream effectors, including Ras, Raf, Rac, JNK, CDC42, p38, pERK, AKT, mTOR, S6 kinase, calcineurin, NFAT, and STATs [9,18,19]. Mechanistic insight into the activation and transducer coupling of the CCK1R requires structural understanding of ligand binding and transducer engagement. However, no structures of the CCK1R, either in inactive or active states, have been solved. Moreover, we have recently demonstrated that increased cholesterol in the plasma membrane that routinely occurs in obese patients impairs CCK-mediated Gq/11 protein signalling from the CCK1R [2022]. As such, obese patients are liable to be refractory to drugs that mimic CCK activation of this pathway, and this has likely contributed to lack of clinical success of drugs developed using Gq/11-mediated pathways as the primary endpoint.

In this study, we used cryo-EM to determine structures of the CCK1R bound to the CCK peptide agonist, CCK-8, and 2 different transducer proteins: GαsGβ1γ2 and a chimeric Gq protein mimic (with Gβ1γ2) that was recently used to determine the structure of Gq/11 coupled 5HT2A and orexin 2 (OX2) receptors [23,24]. As seen with other Gq/11–GPCR complexes, the Gq–αH5 bound to a relatively narrow pocket in the CCK1R core. Surprisingly, the backbone of the CCK1R and volume of the G protein binding pocket were essentially equivalent when Gs was bound, with the Gs αH5 displaying a conformation that arises from “unwinding” of the far carboxyl-terminal residues, compared to canonically Gs coupled receptors. Thus, integrated changes in the conformations of both the receptor and G protein are likely to play critical roles in the promiscuous coupling of individual GPCRs.

Results and discussion

CCK1R signalling is differentially modulated by the cellular environment

The CCK1R can couple to multiple G proteins including Gq/11 and Gs family proteins [9], but the potential importance of non-Gq/11 pathways is not clear. In HEK293s cells stably expressing the CCK1R, CCK-8 was approximately 1,000-fold more potent in mobilisation of intracellular Ca2+ (iCa2+) downstream of Gq than Gs-mediated cAMP production (Fig 1A and 1I), consistent with classification of CCK1R as a Gq/11 coupled receptor. As previously reported [25], increasing plasma membrane cholesterol (here delivered as a conjugate with methyl-β-cyclodextrin [MβCD]) led to an approximately 10-fold loss of CCK-8 potency (Fig 1B and 1I). In contrast, the increased cholesterol augmented peptide potency in cAMP production by approximately 10-fold (Fig 1B and 1I) such that potency for the 2 pathways was only approximately 30-fold different. The increased potency for cAMP production was paralleled by a similar increase in whole cell binding affinity (Fig 1C and 1I), which has previously been observed for CCK1R expressing cells in high cholesterol states [25,26]. Remarkably, in cells with genetic deletion of Gq/11 proteins, there was also higher CCK-8 potency in cAMP production, where increasing cholesterol had no further effect (Fig 1D and 1I). In these cells, however, the affinity of CCK-8 was similar to the parental cells, but cholesterol had reduced ability to increase binding affinity (Fig 1E and 1I). In cells with genetic deletion of Gs, CCK-8 potency for iCa2+ mobilisation was similar to that seen with parental cells, as was the effect of cholesterol to reduce peptide potency (Fig 1F and 1I). Interestingly, CCK-8 binding affinity was higher than seen with parental cells and was no longer sensitive to increased cholesterol (Fig 1G and 1I). Collectively, these data illustrate that the CCK1R has a complex mode of G protein transducer engagement that is regulated by transducer expression levels and the local plasma membrane environment. Moreover, the data support the relevance of Gs coupling to the CCK1R with this also likely to contribute more to pathological signalling of the receptor. We next sought to understand the structural basis for pleiotropic coupling of CCK1R to Gq and Gs proteins.

Fig 1. Effects of G protein association and cellular cholesterol on CCK-8 binding and biological activity.

Shown are data for stable CCK1R-expressing HEK293s cell lines for parental cells or with deletion of Gq/11 or Gs proteins, in the absence or presence of increased cellular cholesterol by treatment with MβCD–cholesterol complex. Receptor density was not different between the cell lines. (A) In untreated cells, CCK was much more potent in stimulating iCa2+ mobilisation than cAMP production. (B) After enhancing cellular cholesterol, CCK-8 potency in the iCa2+ mobilisation assay was reduced, but potency for cAMP production was increased. (C) Increased cellular cholesterol resulted in an increase in CCK-8 binding affinity. (D) In the cell line in which Gq/11 proteins were deleted, CCK-8 potency in the cAMP assay to CCK was increased and was not affected by cholesterol enhancement, whereas (E) CCK-8 binding affinity was not significantly different. (F) In the cell line in which Gs protein was deleted, CCK-8 potency in the iCa2+ assay and sensitivity to increasing cellular cholesterol were equivalent to parental cells, whereas (G) CCK-8 binding affinity was insensitive to altered cholesterol. (H) Schematic of CCK1R signalling. Under conditions of normal membrane cholesterol, CCK-8 signals predominantly via Gq/11 proteins with weak activation of Gs protein. With high cholesterol, there is increased Gs-mediated and decreased Gq/11-mediated signalling. (I) Quantitative pharmacology analysis of the data in panels A–G. Values are mean ± SEM from 6 to 8 independent experiments performed in duplicate. ** P < 0.01; significant differences were determined using a Mann–Whitney test for treated cells versus cells without MßCD–cholesterol treatment. Data files for graphs are provided as S1 Data. CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; iCa2+, intracellular Ca2+; MβCD, methyl-β-cyclodextrin.

Binding of heterotrimeric G proteins to activated GPCRs is inherently unstable as the role of the GPCR is to act as a guanine nucleotide exchange factor (GEF) to rapidly activate and release the Gα and Gβγ protein subunits and prime subsequent second messenger activation events. As such, biochemical methods to stabilise binding of the Gα and Gβγ subunits to each other and to the activated receptors are required [48]. The most robust approaches have been for GPCR complexes with Gs, where a combination of nanobody 35 (Nb35) with dominant negative Gαs, or mini-Gαs that lacks the mobile α-helical domain (AHD), has been used successfully for numerous receptors [4,10]. In contrast, complexes of GPCRs with Gq/11 proteins have been more difficult. The limited success has been with chimeric G proteins. In one approach, used with the muscarinic M1 receptor, chimeras of G11 with the αN of Gi were generated to enable the use of the short chain antibody, scFv16, to bridge this αN and the β-subunit of the obligate Gβγ dimer [27]. For the 5HT2A and OX2 receptors, further engineering was required [23,24]. In this case, a chimera of mini-Gs substituted with (i) Gq residues proximal to the receptor interface (including the carboxyl-terminal αH5); and (ii) the far αN of Gi (mGsqi; S1I Fig). Nonetheless, residues in the 5HT2A receptor that interacted with the Gq mimetic protein were validated by mutagenesis in assays with wild-type (WT) Gq protein [23].

In the current study, we used the mGsqi chimera in combination with scFv16 to maximise stability of ternary complexes with CCK-8 and CCK1R, where the mGsqi was fused to the receptor carboxyl terminus, which was required for original complex formation. A 3C cleavage site was introduced prior to the G protein to allow for cleavage of the G protein following complex formation (S1A Fig). For complexes with Gs, we utilised a dominant negative form of Gαs, with further stabilisation of the complex achieved using Nb35. The CCK1R for this complex was modified to include a HA signal peptide, FLAG epitope tag, and the N-terminal sequence of the M4 mAChR that we have previously demonstrated to improve expression yields [28,29]. These sequences were followed by a 3C cleavage site to allow removal after affinity purification (S1B Fig). The constructs (post cleavage equivalents) were not different from WT receptor in Gq-mediated iCa2+ mobilisation assays (S1C Fig). Receptor, Gα (GαsDN; mGαsqI as a fusion with CCK1R), and Gβ1γ2 were co-expressed in Tni insect cells with complex formation initiated by the addition of 10 μM CCK-8. Complexes were further stabilised through addition of apyrase, to remove guanine nucleotides, and by addition of either scFv16 (mGsqi) or Nb35 (GsDN). Complexes were solubilised in lauryl maltose neopentyl glycol (LMNG)/cholesteryl hemisuccinate (CHS), followed by anti-FLAG affinity purification, treatment with 3C enzyme and separation by size exclusion chromatography (SEC) to yield monodisperse peaks containing the protein complex (S1D–S1H Fig). Following vitrification, samples were imaged on a Titan Krios with data processed to yield 3D consensus reconstructions of 2.5 Å and 2.0 Å resolution at gold standard Fourier shell correlation (FSC) 0.143, respectively, for the CCK-8/CCK1R/mGsqi and CCK-8/CCK1R/GsDN complexes (S1J and S1K Fig, Fig 2A–2F, S1 Table).

Fig 2. Cryo-EM structure of CCK-8/CCK1R in complex with DNGαs/Gβ1γ2/Nb35 or mGαsqi/Gβ1γ2/scFv16.

(A) Consensus cryo-EM map of the CCK-8/CCK1R/mGαsqi/Gβ1γ2/scFv16 complex resolved to 2.45 Å (FSC 0.143). (B) Cryo-EM map following focused refinement of the receptor resolved to 2.5 Å (FSC 0.143). (C) Molecular model of the complex (the scFv16 was omitted from modelling). (D) Consensus cryo-EM map of the CCK-8/CCK1R/DNGαs/Gβ1γ2/Nb35 complex resolved to 1.95 Å (FSC 0.143). (E) Cryo-EM map following focused refinement of the receptor resolved to 2.1 Å (FSC 0.143). (F) Molecular model of the complex. The maps and models are coloured according to the labels on the figure. The receptor and G proteins are displayed in ribbon format. The CCK-8 peptide and modelled cholesterol are displayed in ball and stick representation. (G) EM density for the CCK-8 peptide ligand (yellow, stick representation coloured by heteroatom) and proximal waters (red spheres) zoned at 1.8 Å. (H) CCK-8 (yellow) is bound with the carboxyl terminus of the peptide buried within the TM bundle and makes extensive interactions with CCK1R (green, ribbon format). (I) Y2-SO3CCK makes interactions with R197ECL2 and C196ECL2. (J) W5CCK makes interactions with N3336.55 and I3527.25. (K) The terminal F8-NH2CCK forms hydrogen bonds with C942.57, N982.61, and Y3607.43. CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; cryo-EM, cryo-electron microscopy; DNGαS, dominant negative form of GαS; FSC, Fourier shell correlation.

For the complex with the Gq mimetic, local resolution was highest for Gβ and Gα subunits that are stabilised by scFv16, with lowest resolution for the extracellular face of the receptor and peptide (S2A Fig). Additional focused refinements were performed on the receptor and G protein (S2B and S2C Fig), leading to substantially improved resolution of these domains that allowed modelling of the Ras domain of the Gα, Gβ, Gγ, CCK1R, and CCK-8, including side-chain rotamers for the receptor with the exception of ICL3 residues 244 to 301 that were poorly resolved and not modelled (Fig 2C, S2D and S3A and S3B Figs).

For the complex with Gs, local resolution was highest for the G protein and G protein–receptor interface, with lowest resolution at the extracellular face of the receptor (S2E Fig). Additional focused refinement of the receptor provided improvement to the local resolution, including the peptide binding site (S2F Fig), allowing accurate modelling of most side-chain rotamers and also waters within the binding pocket and receptor–G protein interface (Fig 2F and 2G, S2G, S3A and S3B Figs).

The backbone of the receptor and location of CCK-8 in the binding pocket were highly similar for both the Gq mimetic and Gs bound complexes with root mean square deviations of 0.6 Å for the receptor and 0.3 Å for the peptide. The greatest divergence between structures was observed in the position of ICL2 that was translated 2.5 Å away from the receptor core in the complex with the Gq mimetic (S3A Fig, S1 Video). While ECL1 was unstructured, ECL2 formed a twisted β-hairpin and ECL3 a short α-helix. On the intracellular face, ICL2 presented as a short α-helix (S3A Fig). While both G proteins penetrated the core of the receptor to a similar depth, there were translational and rotational differences in the orientation of G proteins relative to the receptor (S3B Fig), described in detail below.

CCK-8 binding

CCK-8 bound into the consensus structures of both CCK1R-DNGs and CCK1R–mGsqi in essentially identical poses (S3C Fig). As the binding site resolution was higher with the Gs complex, the interactions between CCK-8 and the receptor are described for this structure (Fig 2G–2K, Table 1). The CCK-8 peptide is bound to the receptor in an extended conformation, with the carboxyl terminus buried deep within the core of CCK1R and the N-terminus pointing up and out of the ligand binding cavity (Fig 2H). The amidated carboxyl-terminal F8CCK forms a hydrogen bond network to C942.57, N982.61, and Y3607.43 of the CCK1R, as well as van der Waals interactions with L3567.39 (Fig 2K, Table 1). The carboxyl terminus is further stabilised by the side chain of D7CCK, which forms salt bridges to H2105.39 and R3366.58 as well as a hydrogen bond to Y1764.60. The centre of the peptide is primarily coordinated by a series of van der Waals interactions; of note, W5CCK forms a hydrogen bond to N3336.55 as well as van der Waals interactions to I3527.25 (Fig 2J, Table 1). The sulphated tyrosine (Y2-SO3CCK), although close to the N-terminus of the peptide, is folded over pointing back down towards the core of the receptor. It forms a number of salt bridges to R197ECL2 of the β-strand of ECL2, as well as a hydrogen bond to the backbone of C196 ECL2. R197ECL2 is further coordinated by hydrogen bonds to the backbone of M6CCK of CCK-8 (Fig 2I). The high resolution of this structure enabled modelling of 3 water molecules within the CCK-8 binding pocket, one of which (H2O-2) is coordinated by the SO3 group of Y2-SO3CCK, and also interacts with the backbone of M6CCK and N982.61 of CCK1R. The location of CCK-8, which is deep within the TM binding pocket, is observed in other class A peptide-bound receptor structures, such as the OX2R, which also binds a carboxyl terminally amidated peptide (OxB) [24]. The similar depth of OxB within the OX2R binding pocket also enables hydrogen bonding to Y7.43. OxB also extends out towards the extracellular surface, yet orients towards ECL3 at the N-terminus, whereas CCK-8 forms interactions with ECL2 of CCK1R (S3D Fig). The negatively charged nature of CCK-8 side chains favours the relatively positively charged pocket of CCK1R as opposed to the negatively charged pocket observed for OX2R (S3E and S3F Fig).

CCK-8 interactions are, in part, supported by previous mutagenesis studies. Select mutants of C942.57, R197ECL2, N3336.55, I3527.25, L3567.39, and Y3607.43 cause a decrease in the potency of CCK peptides that range from 30-fold to 9,300-fold [3032]. However, it is important to note that the binding mode of CCK-8 to its receptor has been controversial with the peptide carboxyl terminus predicted to occupy either a shallow or deep pose, depending upon the method of investigation [31,33]. We have recently speculated that the deep pose might be equivalent to the higher affinity state seen in the presence of high cholesterol. The peptide location in the consensus maps is consistent with the deeper pose. In the absence of Gq/11 proteins, CCK-8 potency for Gs-mediated cAMP production is higher and insensitive to increased cholesterol. As such, it is possible that CCK-8 might favour the more stable, deeper pose when bound to Gs. For both preparations, the complexes were solubilised in detergent supplemented with CHS and consequently may more closely mimic a high cholesterol type environment leading to enrichment of the deeper binding mode. The CCK1R contains 4 consensus cholesterol binding motifs [25], and both complexes are surrounded by annular lipids (S4D and S4E Fig), including density that could be modelled with CHS located at the interface of TM2 and TM4 (S4A–S4C Fig). The functionally relevant allosteric cholesterol binding domain has been localised to a CRAC motif low in TM3 [25,34]. In the consensus structures, weaker densities that might correspond to cholesterol are present in the cryo-EM maps, with the density extending to ICL2 (S4D and S4E Fig), suggesting that bound cholesterol may modulate the conformational dynamics of this loop. In other class A GPCRs, including the β2-AR [35], hydrophobic residues of ICL2 interact with the junction of the αN and αH5 and have been linked to G protein activation. The density for ICL2 is well resolved for the Gs complex, but there is additional density in the Gq-bound complex that might indicate higher relative dynamics (S4F Fig), and this was also observed in 3D variability analysis (3DVA) of the principal components of motion within the cryo-EM data (S2 Video). In both CCK1R complexes, the receptor was highly dynamic, undergoing twisting and rocking motions, and this was particularly true for the extracellular regions of the receptor and CCK-8 peptide binding site (S2 Video). This likely reflects differential stability of the peptide in the deep binding pose, even when stabilised by G protein binding. Nonetheless, additional work will be required to better understand the structural basis for the differences reported in modes of peptide binding to the CCK1R and how this is regulated by different lipids.

CCK1R activation mechanism

The transmembrane core of the active-state CCK1R is similar to other active-state class A GPCR structures [6] with the intracellular side of TM6 occupying a similar location to other active, Gq/11-coupled, receptors [23,24,27], creating a binding site for the insertion of the αH5 of the G proteins. While there are no inactive-state structures available for the CCK1R, the rotameric positions of residues in conserved class A activation motifs such as the CWxP, PI(T)F, NPxxY, and E/DRY motifs exhibited strong overlap with the equivalent residues in the active OX2R complex [24] (S5 Fig). As such, the transitions observed between the inactive and active OX2R serve as a template for the likely reorganisation of residues in these activation motifs. At the bottom of the peptide-binding pocket, the aromatic edge of F8CCK interacts with F3306.52 that, in turn, interacts with W3266.48 of the CWxP motif (S5A Fig). The position of W3266.48 is such that F3226.44 of the PI(T)F motif moves outward. This outward rotation of F3226.44 is consistent with other class A GPCRs and is proposed to initiate the outward movement of TM6 that is necessary for G protein binding (S5B Fig). Further below the PI(T)F motif is residue Y3707.53 within the NPxxY motif, which moves inwards, promoting an interaction with Y2295.58 through a bridging water molecule (S5C Fig). This tyrosine “water lock” is speculated to stabilise the active conformation of class A GPCRs [36,37]. The stabilisation of Y2295.58 by the “water-lock” allows this residue to interact with R1393.50 from the E/DRY motif, following release from an ionic interaction proposed to occur between R1393.50 and E1383.49 in inactive state structures (S5D Fig).

CCK1R-G protein interface

Overall, the structures of CCK1R/Gs and CCK1R/mGsqi are similar and display the prototypical receptor/G protein interface; however, they also exhibit marked differences in their mode of G protein binding. When the structures are overlayed on the receptor, the G proteins display substantive differences in their orientation, with differences in the Gα protein propagated to the Gβγ subunits (S3B, S6A, and S6B Figs, Fig 3A, S1 Video). For example, while the base of the Gα α5 helices overlay, the carboxyl terminus of this helix in Gs is rotated approximately 9.5° outwards from the core of the receptor, relative to mGsqi (Fig 3C and 3D, S1 Video). In combination with unwinding of the carboxyl-terminal “hook” of Gs (discussed below), the carboxyl-terminal residues are oriented out from the receptor core between TM6 and TM7/H8, and this allows the conserved L393H5.25 (superscript, CGN G protein numbering system [38]; Fig 3B) to form van der Waals interactions with M3737.56 and R3106.32 (Fig 3E, Table 2). The carboxyl terminus of the αH5 of Gs is further stabilised by a hydrogen bond from N3746.47 to the backbone of Q390H5.22. Furthermore, the conserved L388H5.20 sits in between I1433.54 and K3086.30, forming close contacts and potentially contributing to stabilisation of TM3 and TM6 (Fig 3E, Table 2). The rotation inwards of the αH5 of mGsqi places the conserved L393H5.25, much further inwards (7.6 Å), allowing it to sit in a hydrophobic pocket formed by V3116.33 and L3156.37, and in close proximity to R1393.50 of the DRY motif (Fig 3F, Table 2). This shift inwards results in fewer interactions with TM7 and H8, compared to Gαs, with only R3768.49 forming a hydrogen bond to R389H5.21. This shift inwards allows the conserved Y391H5.23 to hydrogen bond to Q153ICL2, potentially contributing to conformational positioning of ICL2 (Fig 3F, Table 2); this bond is not observed in the Gs-bound structure. The non-conserved N387H5.19 forms a hydrogen bond to the backbone of A1423.53 at the base of TM3 (Fig 3F, Table 2). In Gs, this corresponds to H387H5.19, which can also interact with A1423.53 but potentially forms an additional hydrogen bond to R150ICL2 (3.4 Å), further contributing to stabilisation of ICL2. In 3DVA of the cryo-EM data to extract principal components of motion for each of the CCK1R complexes, the αH5 carboxyl terminus was more stable for the mGsqi protein than the corresponding region of the Gs protein (S3 Video), despite greater motion overall, when comparing the entire G protein relative to the receptor (S2S4 Videos).

Fig 3. G protein interactions with activated CCK1R.

(A) Overlay of Gα subunits bound to the CCK1R highlighting the position of the magnified section in panels B–G. (B) The sequences of the Gα carboxyl terminus (αH5) for Gαs, Gαq, or the chimeric mGαsqi protein. Residues common to both parental G proteins are coloured light blue, amino acids unique to Gs are coloured black, and those of Gq are coloured red. (C, D) There is an approximately 9.5-degree difference in the position of the carboxyl terminus of the 2 G proteins relative to the origin of the αH5. (E, F, H, I) Gαs protein (E, H) and the Gαq-mimetic protein (F, I) form distinct interactions with CCK1R, illustrated from the top of the αH5 (E, F) or the junction of the αN and α5 helices that interacts with ICL2 of the CCK1R (H, I). Protein backbone is illustrated in ribbon format with Gαs in gold (CCK1R, light green) and mGαsqi in blue (CCK1R, dark green). Side chains from the G protein or receptor that interact are displayed in stick format, coloured by heteroatom. Dashed lines indicate H-bonds. G protein residues are numbered according to the CGN G protein numbering system [38]. αH5, α5 helix; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.

Major differences were also observed between the consensus structures in the location and orientation of the αN helix. For mGsqi, the αN helix is rotated outwards from the receptor by approximately 11.5° (Fig 3G) that is accompanied by a 2.5 Å shift in ICL2 away from the receptor TM bundle (S3A Fig, Fig 3G, S1 Video). In both structures, L147ICL2 is buried in a hydrophobic pocket within the α subunit, formed by the αH5, β2-β3 loop, and the top of the β1 strand (Fig 3H and 3I). For Gs, L147ICL2 is buried deeper into the pocket, interacting with H41S1.02, V217S3.01, F376H5.08, and I383H5.15. Moreover, in the Gs-bound complex, ICL2 is further stabilised by hydrogen bonds between Q148ICL2 and R150ICL2 of the receptor and D215S2S3.01 and R38HNS1.02 of the G protein, respectively (Fig 3H). For mGsqi, L147ICL2 also forms interactions within this hydrophobic pocket, which is comprised of L41S1.02, V217S3.01, F376H5.08, and L383H5.15, yet does not bind as deeply (Fig 3I). ICL2 in this complex is further stabilised by a hydrogen bond between R38HNS1.02 and the backbone of V151ICL2 and the previously described hydrogen bond between Q153ICL2 and Y391H5.23 (Fig 3I).

In the 3DVA, the mGsqi protein heterotrimer (with the exception of the more stable αH5) undergoes substantially greater movements than seen for the Gs-bound complex (S4 Video). The more limited motion of Gs is likely due to transient interactions between ICL3 and the S6-H4 loop of the Gα-subunit that is relatively stable in most of the principal components of motion in the 3DVA (S2 Video). Although not well resolved in either structure, there is more robust density for the ends of TM5 and TM6 in the Gs-bound complex versus the mGsqi-bound complex in the consensus reconstructions (S2 Fig), consistent with the observed interaction.

For both complexes, there is only limited contact with the Gβ1 subunit with only poor density in the cryo-EM maps for side chains of residues located at the receptor-Gβ interface.

Comparison of CCK1R G protein engagement with coupling of canonical G protein partners in other GPCRs

Gq/11 family proteins.

The CCK1R is preferentially coupled to Gq/11 proteins. Few other structures of GPCRs (5HT2AR, OX2R, and M1 AChR) bound to Gq mimetic proteins have been determined [23,24,27], where Gq or G11 is also the primary transducer. In each of these receptors, TM6 remains in an extended helical conformation that is translated out at the intracellular base relative to inactive structures [23,24]; the G protein αH5 binds into the narrow cavity formed by this translational movement (S5 and S7 Figs). Overlay of the CCK1R/mGsqi complex structure with each of these other receptor–G protein complexes revealed good correlation in the location and orientation of the G protein and in the conformation of the far carboxyl-terminal residues of the αH5 (S7A–S7C Fig). The largest difference was observed between the CCK1R/mGqsi and the M1 AChR/G11/i complexes, where there both the α5 and αN helices were translated relative to each other (S7C Fig); nonetheless, the conformation of the G protein itself is very similar. The M1 AChR/G11/i is the only GPCR-Gq/11 complex solved where the Gα subunit is primarily the Gq/11 sequence, and this could contribute to the observed differences. However, it is important to note that in the 3DVA of the CCK1R/mGsqi cryo-EM data, all the conformations presented in the available consensus structures of the active M1 AChR, OX2R, and 5HT2AR are sampled (S2 and S4 Videos). As such, sample preparation and vitrification conditions could also contribute to the observed differences, in addition to the potential for real distinctions in the most stable conformations for each complex.

Gs proteins.

The Gs protein heterotrimer was the first transducer to be solved in complex with an activated GPCR [39], and multiple complexes with Gs have now been determined for class A and class B GPCRs where Gs is the primary transducer [7,1012,4044]. These structures have revealed both common and diverse features that govern Gs binding. In the inactive GDP-bound Gαs protein, the αH5 interacts with the αN helix and β1 sheet, with the far carboxyl terminus assuming the bulky “hook” conformation that is prototypical of the active G protein conformation (Fig 4E and 4F). In complex with activated GPCRs, the αH5 is rotated anti-clockwise and translated away from the nucleotide binding site (S5 Video). In most class A GPCR complexes, and all class B GPCR complexes, the bulky “hook” conformation is maintained with binding into the receptor intracellular binding cavity, primarily enabled by a large outward movement at the base of TM6 following receptor activation [7,10] (Fig 4). In prototypical receptors, such as the β-ARs or the adenosine A2AR, this is facilitated by kinking of TM6 (Fig 4A, 4G and 4I), and this is even more marked in class B GPCRs [40] (Fig 4K and 4L). This was initially thought to be a required feature for Gs coupling, at least for receptors where Gs is the primary transducer [7,9,10]. Recent structures of class A GPCRs from different evolutionary subclades have demonstrated that these receptors can bind and activate Gs through alternative mechanisms. In both the bile acid receptor, GPBAR [12], and the prostanoid receptor, EP4R [11], TM6 is an unkinked, extended α-helix, similar to the TM6 conformation in structures of the active Gq/11 coupled receptors (Fig 4H and 4J, S7 Fig), with a correspondingly narrow pocket for binding of the carboxyl-terminal αH5. In the GPBAR–Gs complex, the αH5 is in the prototypic “hook” conformation, and this is accommodated by a shallower engagement with the receptor core that is nonetheless stabilised by more extensive interactions of the Ras domain with ICL3 and TM5 that has a markedly extended, stable, helix [12]; a similar elongated TM5 helix and extended interactions with the Ras domain is observed in the GPR52–Gs structure [41]. Nonetheless, the bulky “hook” conformation is maintained in these structures, suggesting that it is energetically favoured for Gs proteins. In contrast, in the CCK1R–Gs structure, the far carboxyl-terminal residues are “unwound” leading to a less bulky conformation, and the αH5 binds to the same depth as both the mGsqi protein in the CCK1R structure and the Gs protein in prototypical structures, with the carboxyl-terminal hydrophobic Leu residues oriented towards the lipid/detergent interface (Fig 4A, 4B and 4D). Intriguingly, in the EP4R that preferentially couples to Gs, unwinding of the “hook” also occurs (S5 Video), enabling the αH5 to bind to similar depth in the narrower receptor cavity, although here the carboxyl-terminal residues orient between the base of TM7 and TM1 [11] (Fig 4J). These data demonstrate that, while there is a common mode for Gs to engage with GPCRs, functional engagement can occur by multiple divergent mechanisms in a receptor-dependent manner for both canonically coupled GPCRs and those, like CCK1R, that preferentially engage other G protein subfamilies; these diverse modes of binding contribute to the difficulties in using bioinformatic and computational approaches to predict G protein selectivity. Further investigation will be required to understand GPCR–Gs interactions that can trigger destabilisation of the Gs αH5 “hook” conformation that enables novel modes of engagement with receptors; this will be necessary for prediction of functional Gs binding to GPCRs where limited outward movement of TM6 is an intrinsic structural feature.

Fig 4. Gαs adopts a carboxyl terminally extended conformation of the αH5 to enable binding to CCK1R.

(A–D). The far carboxyl terminus of the αH5 of Gαs forms a bulky “hook” conformation for binding to the prototypical Gs-coupled β2-AR (A–C) and occupies a large intracellular binding cavity relative to Gs-bound to the CCK1R that has a narrower binding cavity with binding facilitated by formation of an extended conformation of the Gαs carboxyl terminus (A, B, D). In the inactive Gαs-GDP, the Gs carboxyl terminus exhibits the “hook” conformation indicating that this is the principal ground state conformation (E, F). (G–L) Comparison of the conformation and orientation of Gαs when bound to CCK1R relative to class A, A2AR (G, PDB:6GDG), GPBAR (H, PDB:7CFM), β1-AR (I, PDB:7JJO), and EP4R [J, PDB:7D7M], or class B, GLP-1R (K, PDB:6X18) and SCTR (L, PDB:6WZG) that couple predominantly to Gs. Overall, the receptors engage Gs via wide outward movement of TM6 to accommodate the carboxyl-terminal hook motif. However, the GPBAR interacts with Gs in a narrower cavity through shallower engagement (H), while the EP4R also has a smaller intracellular pocket where Gs engagement is facilitated by unwinding of the far carboxyl terminus of the αH5. However, unlike CCK1R, the side chains are directed into the junction of the base of TM7 and TM1. αH5, α5 helix; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; SCTR, secretin receptor.

Currently, only 1 other GPCR has been solved with 2 different G protein subfamily transducers: the GCGR bound to Gs or Gi [14]. For this receptor, the backbone conformation of the receptor was equivalent, regardless of the bound G protein. Here, the default conformation was the prototypical open pocket that facilitates Gs binding with the less bulky Gi1 protein binding into the same pocket with fewer interactions [14]. In the current study, the CCK1R also exhibited the same backbone conformation, regardless of the bound G protein, but instead this was enabled by conformational change within the Gs protein that allowed it to bind into the smaller CCK1R intracellular binding pocket. While much more work is required, the current data support the contention that the intrinsic conformational flexibility/stability of the receptor [9,45] is a critical feature in modes of G protein coupling for both primary and secondary transducers. The current work also provides supporting evidence for conformational flexibility of the G protein αH5 as a mechanism for promiscuous coupling.


There is much interest in the mechanistic basis for how individual GPCRs bind to different G protein subfamilies and in the features that allow both selectivity and promiscuity in G protein engagement and activation. Herein, we demonstrated that the efficiency and selectivity of G protein coupling could be markedly altered through alterations to the availability of different transducers, as well as by plasma membrane cholesterol (Fig 1). In particular, the efficiency of Gs coupling was markedly augmented by either high cholesterol or absence of the primary (Gq/11) transducers, demonstrating that the local environment of the receptor within a cell is also critical for the mode of transducer engagement. Differential transducer engagement has been reported for different cellular compartments, linked to different receptor conformations [46], and our current observations expand the potential mechanisms for such observations. Our work supports a model for G protein interaction where the extent of GPCR conformational change that occurs upon agonist activation is intrinsic to the individual receptor, but where conformational dynamics within the primary activated state are likely to play a substantial role in G protein coupling and activation. New GPCR-transducer structures are revealing increasing complexity in the mechanisms that enable G protein coupling and activation, and greater breadth in the number of agonist-GPCR-transducer complexes will be required to fully understand the molecular rules that govern G protein selectivity.

Materials and methods

Pharmacological studies


Peptide ligands, natural CCK-26-33 (CCK-8), and an analog for radiolabeling, D-Tyr-Gly-[(Nle28,31) CCK-26-33], were synthesised in-house as previously described [47]. LANCE cAMP kit and sodium 125Iodine were from Perkin Elmer Health Sciences (Shelton, Connecticut, United States of America). Fluo-8-AM was from AAT Bioquest (Sunnyvale, California, USA). Fetal Clone II was from Hyclone Laboratories (Logan, Utah, USA), and Dulbecco’s Modified Eagle Medium, glutamine, zeocin, and soybean trypsin inhibitor were from Thermo Fisher Scientific (Waltham, Massachusetts, USA). Methyl-β cyclodextrin, 3-isobutyl-1-methyl xanthine and poly-lysine were from Sigma-Aldrich (St Louis, Missouri, USA). All other reagents were of analytical grade.

Cell lines.

The HEK-293(S) parental cell line and its G protein (Gq, Gs) knockout lines (GsKO, GqKO) generated using the CRISPR/Cas-9 approach [48,49] were kindly provided by Dr. Asuka Inoue (Tohoku University, Miyagi, Japan). Each cell line was transfected with human type 1 CCK receptor using PEI [50], with clonal cell lines expressing similar levels of receptor selected using CCK-like radioligand binding [25]. Cells were grown in Dulbecco’s Modified Eagle Medium supplemented with 10% Fetal Clone II in a humidified atmosphere containing 5% CO2 at 37°C and were passaged approximately twice a week.

Cholesterol modifications.

Cells had their cholesterol composition enhanced using MβCD–cholesterol inclusion complex [51].

Receptor binding assays.

CCK-like radioligand binding assays were performed with intact cells grown in poly-lysine coated 24-well tissue culture plates, as described [52]. Nonspecific binding was determined in the presence of 1 μM unlabeled CCK. All assays were performed in duplicate and repeated at least 3 times in independent experiments. Competition binding curves were analysed and plotted using the nonlinear regression analysis programme in the PRISM software suite v8.02 (GraphPad, San Diego, California, USA).

Intracellular calcium response assays.

CCK-stimulated intracellular calcium responses were quantified in intact cells using Fluo-8-AM using a FlexStation (Molecular Devices, Sunnyvale, California, USA), as described [52]. All assays were performed in duplicate and repeated at least 3 times in independent experiments. Calcium response curves were analysed and plotted as percentages of the maximal stimulation by 100 μM ATP using nonlinear regression analysis in the PRISM software suite v8.02.

Intracellular cAMP response assays.

CCK-stimulated intracellular cAMP responses were measured in intact cells in 384-well white Optiplates using LANCE cAMP kits, as described [53]. Assays were performed in duplicate and repeated at least 3 times in independent experiments. The cAMP concentration–response curves were analysed and plotted using the nonlinear regression analysis in PRISM v8.02.

Statistical comparisons.

Comparisons of experimental groups were assessed using analysis of variance (ANOVA) followed by Dunnett posttest, or using the Mann–Whitney test, as provided in PRISM 8.0 (GraphPad). The threshold for statistical significance was set at p < 0.05.

Structure determination


Human WT CCK1R was modified to include an N-terminal hemagglutinin (HA) signal sequence, FLAG-tag, 22 amino acids of the N-terminus of the M4 muscarinic receptor to improve expression [28,29], a 3C-protease recognition sequence to remove the N-terminal modifications, and a carboxyl-terminal 8xhistadine (8xHis) tag (S1A Fig). This construct was cloned in to the pFastBac vector for insect cell expression and pcDNA3.1 for mammalian expression. A construct without modifications was also cloned into pcDNA3.1 for construct validation. Previously described constructs were used to express the heteromeric G protein in insect cells, including a dominant negative form of GαS (DNGαS) and a dual expressing vector containing Gγ2 and 8xHis tagged Gβ1 [8,54]. 8xHis tagged Nb35 in pET20b was obtained from B. Kobilka [39]. For the CCK1R/mGsqi complex, the CCK1R was modified to include the HA signal sequence, N-terminal FLAG-tag, and carboxyl-terminal 3C-protease recognition site, 8xHis-tag and mGsqi (S1B Fig) [55].

Insect cell expression.

CCK1R, DNGαS, and Gβ1γ2 were co-expressed in the Tni insect cell line (Expression Systems, Davis, CA, USA) using the Bac-to-bac baculovirus system (Invitrogen, Carlsbad, CA, USA). The Tni insect cells were grown to a density of 4 million cells/ml in ESF 921 serum free media (Expression Systems) before infection with a 4:2:1 ratio of CCK1R:DNGαS:Gβ1γ2 baculoviruses. Insect cells were harvested by centrifugation at approximately 48 hours post infection, and cell pellets were stored at −80°C. For the CCK1R/miniGsqi similar methods were used, except a 4:1 ratio of CCK1R–mGsqi:Gβ1γ2 baculoviruses was used.

Nb35 and ScFv16 expression and purification.

Nb35 was expressed in the periplasm of BL21(DE3) Rosetta Escherichia coli cell line using an autoinduction method [56]. Transformed cells were grown at 37°C in a modified ZY media (50 mM Phosphate buffer pH 7.2, 2% tryptone, 0.5% yeast extract, 0.5% NaCl, 0.6% glycerol, 0.05% glucose and 0.2% lactose), in the presence of 100 μg/ml carbenicillin and 35 μg/ml chloramphenicol. At an OD600 of 0.7, the temperature was changed to 20°C for approximately 16 hours before harvesting by centrifugation and storage at −80°C. NB35 was purified as described previously by extracting the periplasm supernatant and Ni-affinity chromatography [57].

ScFv16 was expressed in the Tni insect cell line as an excreted product using baculovirus. Media was harvested by centrifugation 72 hours post infection and chelating agents quenched by the addition of 5 mM CaCl2. The media was separated by precipitation by centrifugation and batch bound to EDTA-resistant Ni-Sepharose resin. The column was washed with a high salt buffer (20 mM HEPES pH 7.2, 500 mM NaCl, and 20 mM imidazole), followed by a low salt buffer (20 mM HEPES pH 7.2, 500 mM NaCl, and 20 mM imidazole), before elution in 20 mM Hepes pH 7.5, 100 mM NaCl, and 250 mM imidazole. The eluted protein was dialysed to 20 mM Hepes pH 7.5 and 100 mM NaCl before storage at −80°C.

CCK1R/CCK-.8/DNGαS complex purification.

Insect cell pellet from 1 L of culture was thawed and solubilised in 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl2, 5 mM CaCl2, 0.5% LMNG (Anatrace, Maumee, OH, USA), 0.03% CHS (Anatrace), and a Roche cOmplete Protease Inhibitor Cocktail tablet (Sigma-Aldrich, North Ryde, New South Wales, Australia). The resuspended pellet was homogenised in a Dounce homogeniser and complex formation initiated by the addition of 10 μM CCK-8, 5 μg/ml NB35 and 25 mU/ml apyrase (NEB, Notting Hill, Victoria, Australia). The solubilised complex was incubated with stirring at 4°C for 2 hours before insoluble material was removed by centrifugation at 30,000 g for 30 minutes. The solubilised complex was batch bound to equilibrated M1 anti-Flag affinity resin, rotating at 4°C for 1 hour. The resin was packed into a glass column and washed with 20 column volumes of 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl2, 0.01% LMNG, 0.0006% CHS and 1 μM CCK-8 in the presence of 5 mM CaCl2, before elution in the same buffer with 5 mM EGTA and 0.1 mg/ml Flag peptide. Eluted complex was concentrated to less than 500 μL in an Amicon Ultra-15 100 kDa molecular mass cut-off centrifugal filter unit (Millipore, Burlington, MA, USA) and further purified by SEC on a Superdex 200 Increase 10/300 GL (Cytiva, Marlborough, MA, USA) with 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl2, 0.01% LMNG, 0.0006% CHS, and 1 μM CCK-8. Eluted fractions were containing complex were pooled and concentrated to 4.1 mg/ml before being flash frozen in liquid nitrogen and stored at −80°C.

CCK1R/CCK-8/mGsqi complex purification.

Insect cell pellet from 1.5 L of culture was thawed and resuspended in a hypotonic solution of 20 mM Hepes pH 7.4, 5 mM MgCl2, and 1 μM CCK-8. The cells were stirred at room temperature for 15 minutes to allow lysis to occur. Cell pellet was collected by centrifugation and solubilised in 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl2, 5 mM CaCl2, 0.5% LMNG (Anatrace), and 0.03% CHS (Anatrace) and a Roche cOmplete Protease Inhibitor Cocktail tablet (Sigma-Aldrich). The resuspended pellet was homogenised in a Dounce homogeniser and complex formation initiated by the addition of 10 μM CCK-8, 5 μg/ml ScFv16 and 25 mU/ml apyrase (NEB). The solubilised complex was incubated with stirring at 4°C for 2 hours before insoluble material was removed by centrifugation at 30,000 g for 30 minutes. The solubilised complex was batch bound to equilibrated M1 anti-Flag affinity resin, rotating at 4°C for 1 hour. The resin was packed into a glass column and washed with 20 column volumes of 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl2, 0.01% LMNG, 0.0006% CHS, and 1 μM CCK-8 in the presence of 5 mM CaCl2, before elution in the same buffer with 5 mM EGTA and 0.1 mg/ml Flag peptide. Eluted complex was concentrated to less than 500 μL in an Amicon Ultra-15 100 kDa molecular mass cut-off centrifugal filter unit (Millipore) and further purified by SEC on a Superdex 200 Increase 10/300 GL (Cytiva) with 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl2, 0.01% LMNG, 0.0006% CHS, and 1 μM CCK-8. The sample was then cleaved with 3C-protease at room temperature for 1 hour and reapplied to SEC. Eluted samples were pooled and concentrated to 4 mg/ml before being flash frozen and stored at −80°C.

SDS-PAGE and western blot.

Purified samples were analysed by SDS-PAGE and western blot. Samples were applied to precast TGX gels (Bio-Rad, Hercules, CA, USA) before staining with InstantBlue Coomassie stain (Sigma-Aldrich) or immediately transferred to PVDF membrane (Bio-Rad) for western blot analysis. Western blots were stained with primary rabbit anti-GNAS (Novus Biologicals, Littleton, CO, USA NBP1-31730), primary mouse anti-His antibody (Qiagen, Hilden, Germany, 34660), secondary goat anti-rabbit 800CW antibody (LI-COR Biosciences, Lincoln, NE, USA, 926–32211), secondary anti-mouse 680CW antibody (LI-COR Biosciences, 926–68070) and an in-house made Alexa Fluor 488 conjugated mouse anti-flag antibody. Western blots were imaged on a Typhoon 5 imaging system (Amersham, Little Chalfont, UK).

Vitrified sample preparation and data collection.

Samples (3 μL) were applied to a glow-discharged UltrAufoil R1.2/1.3 300 mesh holey grid (Quantifoil GmbH, Großlöbichau, Germany) and were flash frozen in liquid ethane using the Vitrobot mark IV (Thermo Fisher Scientific) set at 100% humidity and 4°C for the prep chamber with a blot time of 10 seconds. Data were collected on Titan Krios microscope (Thermo Fisher Scientific) operated at an accelerating voltage of 300 kV with a 50 μm C2 aperture with no objective aperture inserted and at an indicated magnification of 130kX in nanoprobe TEM mode. A Gatan K3 direct electron detector positioned post a Gatan BioQuantum energy filter (Gatan, Pleasanton, California, USA), operated in a zero-energy-loss mode with a slit width of 15 eV, was used to acquire dose fractionated images of the samples. Movies were recorded in hardware-binned mode (previously called counted mode on the K2 camera) with the experimental parameters listed in S1 Table using 18-position beam-image shift acquisition pattern by custom scripts in SerialEM [58].

Data processing


A total of 7,146 micrographs were motion corrected using UCSF MotionCor2 [59] and dose weighted averages had their CTF parameters estimated using CTFFIND 4.1.8 [60]. Particles were picked using the crYOLO software package [61] on a pretrained set of weights for GPCRs yielding 6.4 M particle positions. These particles were extracted from the micrographs and subjected to 2D classification and ab initio 3D and 3D refinement in the cryoSPARC (v3.1) software package [62], which resulted in a homogeneous well-centred particle stack containing 1 M particles. These were then fed into the RELION (v 3.1) software package for further rounds of 2D and 3D classification, which led to 800 k particles for initial 3D refinement in RELION. These particles where then polished in RELION and underwent a further round of 3D classification and CTF envelope fitting. A final consensus 3D refinement using 643 k particles was performed in RELION. The maximisation step was carried out using the SIDESPLITTER algorithm [63] to yield a final resolution of 1.95 Å (FSC = 0.143, gold standard) for the consensus map. Further, receptor-focused refinements were performed using a mask generated from an initial PDB model and searching a local 1.8 degree Euler angle space.


A total of 7,182 micrographs were motion corrected using UCSF Motioncor2 and dose weighted averages had their CTF parameters estimated using CTFFIND 4.1.8. Particles were picked using the automated template picking routine in RELION 3.1. Moreover, 2.3 M particles were extracted and cryoSPARC was employed to perform 2D classification, ab initio 3D model generation and initial 3D refinement. The resulting particle stack contained 441 k particles, which were then polished in RELION 3.1. The polished particle stack was then fed back into the cryoSPARC software package for a non-uniform 3D consensus refinement and CTF envelope fitting which yielded a 2.44 Å resolution map (FSC = 0.143, gold standard). Due to a large amount of conformational flexibility between the receptor and G proteins, further local refinements in cryoSPARC were used to calculate high quality maps of either the CCK1 receptor (2.57 Å) or the mGsqi G protein complex (2.43 Å) which were used to generate a PDB model.

CCK1R/CCK-8/DNGs model building.

An initial homology model of CCK1R was created using SWISS-MODEL [64] using the active structure of the serotonin 5-HT1B receptor as a template (PDB ID: 6G79). The CCK1R model was placed into the receptor-focused cryo-EM map by the MDFF routine in namd2 [65]. The CCK-8 peptide was manually built using COOT [66], the sulfotyrosine residue was imported from the monomer library (TYS), and geometry restrains were generated with eLBOW within PHENIX [67]. The model was refined with repeated rounds of manual model building in COOT and real-space refinement within PHENIX [68]. The G protein (DNGαS/Gβ1/Gγ2) and NB35 from the structure of GLP-1 receptor-Gs complex (PDB ID: 6B3J) was rigid body placed into the consensus cryo-EM map using the map fitting tool of UCSF ChimeraX [69]. The G protein was further refined to the consensus cryo-EM map with repeated rounds of manual model building in COOT and real-space refinement within PHENIX. Lastly the CCK1R/CCK-8 model was combined with the G protein and real-space refined to the consensus cryo-EM map using PHENIX. The model quality was assessed using MolProbity [70] before PDB deposition.

CCK1R/CCK-8/mGsqi model building.

The higher resolution model of CCK1R/CCK-8 obtained from the GαS structure was rigid-body placed into a receptor-focused cryo-EM map using ChimeraX. The model was refined with repeated rounds of manual model building in COOT and real-space refinement within PHENIX. The β1 and γ2 were obtained from the higher resolution GαS structure, the miniGsqi was modified from the OX2R structure (PDB ID: 7L1U), and the subunits were rigid-body placed in the G protein–focused map. The model was refined with repeated rounds of manual model building in COOT and real-space refinement within PHENIX [68]. Lastly, the CCK1R/CCK-8 model was combined with the G protein and real-space refined to the consensus cryo-EM map using PHENIX. The model quality was assessed using MolProbity [70] before PDB deposition. The scFv16 was not modelled due to poor side-chain density.

Model interaction analysis.

Interactions and hydrogen bonds were analysed using UCSF chimeraX package, with relaxed distance and angle criteria (0.4 Å and 20° tolerance, respectively). The interfaces were further analysed using PDBePISA [71]. Figures were generated using UCSF chimeraX and PyMOL Molecular Graphics System, Version 2.3 (Schrödinger, New York, NY, USA).


3DVA was performed using the cryoSPARC software package, based on the consensus refinements of the complexes. For the CCK1R–mGsqi data, 6 principal components (Comp0 to Comp5) were used, and for the CCK1R–Gs data, 5 principal components (Comp0 to Comp4) were used to analyse the principal motions in the cryoEM data, each separated into 20 frames (frames 0 to 19). Cryosparc 3DVA outputs were used for dynamic analyses of the CCK complexes and visualised using the command vseries as implemented in ChimeraX [69]. The backbones of the consensus refinement models were flexibly fitted into the frames 0 and 19 density maps of the 3DVA principal components using Isolde [72], implemented in ChimeraX [69]. Morphs of models (aligned using the matchmaker command, or aligned by densities) were created in Chimera and ChimeraX [69,73]. Movie editing was performed using Adobe Premiere Pro 2020.

Supporting information

S1 Fig. Expression and purification of CCK-8/CCK1R/G protein complexes.

(A, B) Snake plot of the CCK1R expression constructs for formation of mGsqi (A) or Gs (B) complexes. The construct for mGsqi complex formation contained an N-terminal HA signal sequence (grey shading), followed by a FLAG epitope tag (yellow shading), with a 3C protease cleavage site (red shading) inserted at the carboxyl terminus followed by an 8-His tag (green shading) and the mGsqi (blue schematic). For Gs complex formation, the construct contained an N-terminal HA signal sequence, followed by a FLAG epitope tag, a M4 mAChR N-terminal sequence (blue shading), and a 3C-cleavage site (red sequence) with an 8-His tag fused to the carboxyl terminus. (C) The expression constructs (red circles or blue circles) were cloned into a mammalian expression vector and concentration-responses to CCK-8 in an iCa2+ mobilisation assay were established relative to WT (black circles). (D, E) SEC of affinity purified CCK-8/CCK1R/mGαsqi/Gβ1γ2/scFv16 complex before (D) and after (E) sample cleavage with 3C protease; the peak used for SDS-PAGE analysis is boxed in red. (F) Coomassie blue stained SDS-PAGE of the peak sample from (D) (left panel) or (E) (right panel). (G) SEC of affinity purified CCK-8/CCK1R/DNGαs/Gβ1γ2/Nb35 complex. (H) Coomassie blue stained SDS-PAGE of the peak sample from (G). (I) amino acid sequence of the mGsqi chimera illustrating the origin of the different segments. (J, K) Gold standard FSC curves for the final map and map validation from half maps showing the overall nominal resolutions of 2.5 Å for the CCK1R-“Gq mimetic” complex (J) and 2.0 Å for the CCK1R–Gs complex (K). The data used to generate graph S1C, and the SEC traces in S1D, S1E, and SG are available in S1 Data. Uncropped gels for (F) and (H) are provided as S2 Data. Data for calculation of the FSC curves in S1J and S1K can be accessed in EMDB-23749 and EMDB-23750. CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; FSC, Fourier shell correlation; HA, hemagglutinin; SEC, size exclusion chromatography; WT, wild-type.


S2 Fig. Local resolution and atomic modelling into the cryo-EM density maps.

Local resolution of (A) the consensus map, (B) G protein–focused refinement, and (C) receptor-focused refinement of the CCK-8/CCK1R/mGαsqi/Gβ1γ2/scFv16 complex. (D) Density maps and models are illustrated for all 7 transmembrane helices and ECL2 of CCK1R, the αH5 of the Gα subunit, and the CCK-8 peptide. (E, F) Local resolution of the consensus (E) and receptor-focused (F) maps for the CCK-8/CCK1R/DNGαs/Gβ1γ2/Nb35 complex. (G) Density maps and models are illustrated for all 7 transmembrane helices and ECL2 of CCK1R, the αH5 of the Gα subunit, and the CCK-8 peptide. Protein backbone is displayed in ribbon format with amino acid side chains in stick representation, coloured by heteroatom. The cryo-EM density was zoned at 1.8 Å. αH5, α5 helix; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; cryo-EM, cryo-electron microscopy.


S3 Fig. Comparison of CCK-8 binding interactions with CCK1R in Gs and Gq mimetic protein complexes.

(A, B) Alignment of the 2 structures. (A) Alignment of receptor and CCK-8 peptide. The largest difference in the CCK1R was in the location of ICL2 that is further away from the receptor core in the complex with the Gq mimetic protein. (B) Alignment of the full complex illustrating differences in the engagement and orientation of the G proteins. The receptor and G proteins are displayed in ribbon format. (C) Overlay of CCK-8 and interacting CCK1R residues in the binding pocket for the Gs and Gq mimetic complexes. The CCK-8 peptide and modelled cholesterol are displayed in ball and stick representation. The CCK-8 residues are displayed in stick format, coloured by heteroatom (Gs complex, gold; Gq mimetic complex, yellow). CCK1R side chains that interact with the peptide are shown in stick format (Gs complex, light green; Gq mimetic complex, dark green). (D) Comparison of the CCK-8/CCK1R with OxB/OX2R (blue ligand, pink receptor) binding pockets. The peptides overlap in the location of the amidated carboxyl-terminal tetrapeptide but differ in conformation and position of N-terminal amino acids. CCK-8 interacts more with ECL2 than ECL3, while the reverse is true for OxB. (E) Surface electrostatic potential of the CCK1R binding pocket. CCK1R has a very positive surface charge. (F) In contrast, the OX2R binding pocket has a very negative surface potential. CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.


S4 Fig. The active CCK1R is surrounded by annular lipids.

(A) Alignment of the Gs and mGsqi structures illustrating the location of the Gαs protein and modelled lipid. (B) Model of the cholesteryl hemi succinate (CHS) in the cryo-EM density. (C) The modelled CHS interacts with TM2 and TM4 of CCK1R. (D, E) Receptor-focused maps for the Gs protein-complex (D) and Gq mimetic protein complex (E) are shown, coloured by component (CCK1R, green; CCK-8, yellow; Gαs protein, gold; Gαq-mimetic protein, blue; unmodelled lipids, grey; putative CHS, purple). There is weak cryo-EM density in the predicted binding site for the allosteric cholesterol abutting ICL2 (pink density). (F) The cryo-EM density of ICL2 (zoned at 1.8 Å) in the Gs complex supports a single predominant conformation, while the density in the Gq mimetic complex is less well resolved. CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; CHS, cholesteryl hemisuccinate; cryo-EM, cryo-electron microscopy.


S5 Fig. Comparison of activation motifs between CCK1-active (green) and OX2R-active (pink) and inactive (grey).

(A) CWxP motif. While there is no direct interaction between CCK-8 and W3266.48 of the CWxP motif, residue F8CCK interacts with F3306.52, which, in turn, interacts with W3266.48. Of note, residue 6.48 is not conserved in OX2R, and there is no movement between the inactive and active states at this position. Given the absence of an inactive CCK1R structure the role of the CWxP motif in CCK1R is unclear. Nevertheless, the position of W3266.48 stabilises the outward rotation of F3226.44 within the PI(T)F motif. (B) Comparison of the PI(T)F motif shows this activation motif is largely conserved between CCK1R and OX2R. Upon activation, there is a modest movement of F6.44 for OX2R. CCK1R is even further shifted away from T1293.40 and P2215.50. (C) NPxxY motif. Upon activation, there is a clear rotation of Y7.53 for OX2R. CCK1R Y3707.53 overlays with the active form of OX2R and forms a water mediated interaction Y2295.58. (D) E/DRY motif. In the OX2R, inactive state R3.50 forms a salt-bridge with E3.49; these residues are conserved in CCK1R. Upon activation, R3.50 rotates up and inwards to form a hydrogen bond with Y5.58, the position of these residues overlay with the active CCK1R. CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.


S6 Fig. The Gs and Gq mimetic proteins have distinct orientations in the consensus structures.

(A) Orientation of the G proteins following alignment on CCK1R. The protein backbone is displayed in ribbon format coloured according to the displayed legend. The CCK-8 peptide (yellow; stick and surface representation) and modelled CHS (purple, stick and surface representation) are also shown (main panel). Gs and mGsqi have a different angle of engagement, and this is propagated to larger changes in the relative positions of the Gβ and Gγ subunits (inset panels). (B) Alignment of the Gβ subunits reveals that the Gα subunits have distinct rotational and translational positions in the heterotrimer. CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; CHS, cholesteryl hemisuccinate.


S7 Fig. Comparison of the orientation and conformations of Gq mimetic proteins in class A GPCRs.

Each of the available Gq (Gq mimetic chimera) bound structures is displayed relative to the structure of the CCK1R–mGsqi complex. (A) CCK1R–mGsqi and 5HT2AR-mGsqi (PDB:6WHA). (B) CCK1R–mGsqi and OX2R-mGsqi (PDB:7L1U). (C) CCK1R–mGsqi and M1 mAChR-G11/i chimera [PDB:6OIJ). The structures are aligned to the CCK1R. The protein backbone is shown in ribbon format coloured according to the displayed legends. The carboxyl-terminal residues of the G protein αH5 are shown in stick representation coloured by heteroatom. All receptors have a similar, narrow, intracellular G protein binding cavity with only small differences in the angle or translational position of the αH5 when bound to the receptor (A–C), with greatest difference seen between CCK1R and M1 mAChR complexes (C). αH5, α5 helix; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; GPCR, G protein–coupled receptor.


S1 Table. Data collection and refinement statistics.


S1 Video. Morph between the consensus structures of the CCK-8:CCK1R in complex with mGsqi or Gs.

Structures are displayed in ribbon format with the mGsqi-bound complex in blue, Gs-bound complex in yellow. The morphed coordinates are coloured white. The initial transition shows the full complex, the second transition a close up of the receptor–G protein interface focused on the αH5 of the Gα subunit, and the final transition a close up of the receptor–G protein interface focused on the αN-αH5 junction and receptor ICL2. Morphs between conformations were created in Chimera. The stabilising Nb35 and scFv16 have been omitted for clarity. αH5, α5 helix; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.


S2 Video. 3DVA of the cryo-EM data for CCK1R complexes.

In the first transition, the complex with mGsqi was parsed into 6 principal components with motions for each component displayed side by side. In the second transition, the complex with Gs was parsed into 5 principal components with individual components displayed side by side. For both complexes, the receptor and peptide were highly dynamic in 1 or more of the component trajectories, with the receptor–G protein interface exhibiting greater relative dynamics for the mGsqi complex over the Gs complex. The 3DVA trajectories are displayed suing the ChimeraX Volume Series command. 3DVA, 3D variability analysis; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; cryo-EM, cryo-electron microscopy.


S3 Video. Morph of the start and end frames of component trajectories from 3DVA of the CCK1R-G protein interface.

Maps and models are shown first for the complex with mGsqi followed by the complex with Gs. The first transition illustrates the full complex and region of focus for the subsequent transition that illustrates individual principal components of motion. The modelled protein is displayed in ribbon format and the map in grey transparent surface representation. CCK1R (dark green, mGsqi complex; light green, Gs complex), mGsqi (blue), Gs (gold), Gβ1(light red), Gγ2 (pink), and Nb35 (Gs complex; grey) are shown. 3DVA, 3D variability analysis; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.


S4 Video. Progressive morph between the start and end frames of the individual principal components of motion of CCK1R complexes modelled from 3DVA.

Models of the complexes with mGsqi (left panels) or Gs (right panels) are displayed in ribbon format illustrating the CCK1R-G protein interface from either the “front” (focus on Gα helix 5; upper panels) or “rear” (focus on GαN/ICL2; lower panels). The transitions commence with frame 0 of the first component (0) then frame 19 (component 0) proceeding to frame 0 of the second component [1] then progressively through to the end (frame 19, component 5 (mGsqi); frame 19, component 4 (Gs)). The mGsqi cryo-EM data were parsed into 6 components, while the Gs cryo-EM data were parsed into 5 components. The data illustrate the extent of conformational dynamics for the 2 complexes with greater relative motion overall of the CCK1R–mGsqi complex relative to the CCK1R–Gs complex. 3DVA, 3D variability analysis; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; cryo-EM, cryo-electron microscopy.


S5 Video. Conformational transitions for “activation” of Gαs proteins.

The video displays the different transitions (morph between structures) that Gαs undergoes when moving from the inactive GDP-bound state (PDB: 6EG8) to the G0 state (guanine nucleotide free) induced by binding to selected activated class A or class B GPCRs. Transition 1: inactive to CCK1R-bound. Transition 2: inactive to β2-AR-bound. Transition 3: β2-AR-bound to CCK1R-bound. Transition 4: inactive to GLP-1R-bound to CCK1R-bound. Transition 5: inactive to EP4R-bound to CCK1R-bound. The protein backbone is displayed in ribbon format with the carboxyl-terminal residues of the αH5 shown also in stick format (coloured by heteroatom). Gs-GDP (grey; PDB: 6EG8), CCK1R-bound (gold), β2-AR-bound (blue; PDB: 3SN6), GLP-1R-bound (green; PDB:6X18), EP4R-bound (red; PDB: 7D7M). The αH5 has a “hook” conformation in the inactive G protein, and this conformation is maintained in most active state structures. In contrast, the far carboxyl-terminal residues of the αH5 unwinds to enable binding to the CCK1R. Unwinding of the α-5 helix is also seen with the EP4R complex, but this is accommodated by projection of the carboxyl-terminal amino acid side chains between the base of TM7 and TM1 (see Fig 4J). αH5, α5 helix; CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor; GPCR, G protein–coupled receptor.


S1 PDB. PDB model from the receptor-focused refinement of the CCK-8/CCK1R/Gs complex.

CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.


S2 PDB. PDB model from the G protein–focused refinement of the CCK-8/CCK1R/mGsqi complex.

CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.


S3 PDB. PDB model from the receptor-focused refinement of the CCK-8/CCK1R/mGsqi complex.

CCK, cholecystokinin; CCK1R, cholecystokinin type 1 receptor.


S1 Data. Excel spreadsheet with experimental data used for concentration response and binding inhibition graphs in Fig 1 and S1C Fig, as well as the raw data for the SEC traces in S1D, S1E, and S1G Fig.

SEC, size exclusion chromatography.


S2 Data. Uncropped Coomassie-stained SDS-PAGE gels used for S1F and S1H Fig.



Molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. The work was supported by the Monash University Ramaciotti Centre for Cryo-Electron Microscopy and the Monash MASSIVE high-performance computing facility.


  1. 1. Shukla AK ed. G protein-coupled receptors: Signaling, trafficking and regulation. In: Methods in Cell Biology volume 132. pp. 502 (2016). Elsevier Science. ISBN: 978-0-12-803595-5.
  2. 2. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, et al. The concise guide to pharmacology 2019/2020: G protein-coupled receptors. Br J Pharmacol. 2019;176(Suppl 1):S21–S141. pmid:31710717
  3. 3. Zhao P, Furness SGB. The nature of efficacy at G protein-coupled receptors. Biochem Pharmacol. 2019;170:113647. pmid:31585071
  4. 4. Thal DM, Vuckovic Z, Draper-Joyce CJ, Liang Y-L, Glukhova A, Christopoulos A, et al. Recent advances in determination of G protein-coupled receptor structures. Curr Opin Struct Biol. 2018;51:28–34. pmid:29547818
  5. 5. Munk C, Mutt E, Isberg V, Nikolajsen LF, Bibbe JM, Flock T, et al. An online resource for GPCR structure determination and analysis. Nat Methods. 2019;16:151–162. pmid:30664776
  6. 6. Wang J, Hua T, Liu Z-J. Structural features of activated GPCR signaling complexes. Curr Opin Struct Biol. 2020;63:82–89. pmid:32485565
  7. 7. García-Nafría J, Tate CG. Cryo-EM structures of GPCRs coupled to G(s), G(i) and G(o). Mol Cell Endocrinol. 2019;488:1–13. pmid:30930094
  8. 8. Liang YL, Zhao P, Draper-Joyce CJ, Baltos JA, Glukhova A, Truong TT, et al. Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination. ACS Pharmacol Transl Sci. 2018;1:12–20. pmid:32219201
  9. 9. Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, et al. Illuminating G-protein-coupling selectivity of GPCRs. Cell. 2019;177:1933–1947. pmid:31160049
  10. 10. Glukhova A, Draper-Joyce CJ, Sunahara RK, Christopoulos A, Wootten D, Sexton PM. Rules of Engagement: GPCRs and G Proteins. ACS Pharmacol Transl Sci. 2018;1:73–83. pmid:32219204
  11. 11. Nojima S, Fujita Y, Kimura KT, Nomura N, Suno R, Morimoto K, et al. Cryo-EM Structure of the Prostaglandin E Receptor EP4 Coupled to G Protein. Structure. 2021;29:252–260.e6. pmid:33264604
  12. 12. Yang F, Mao C, Guo L, Lin J, Ming Q, Xiao P, et al. Structural basis of GPBAR activation and bile acid recognition. Nature. 2020;587:499–504. pmid:32698187
  13. 13. Wootten D, Christopoulos A, Marti-Solano M, Babu MM, Sexton PM. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol. 2018;19:638–653. pmid:30104700
  14. 14. Qiao A, Han S, Li X, Li Z, Zhao P, Dai A, et al. B. Wu. Structural basis of Gs and Gi recognition by the human glucagon receptor. Science. 2020;367:1346–1352. pmid:32193322
  15. 15. Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Annu Rev Physiol. 2008;70:239–255. pmid:17937600
  16. 16. Dockray GJ. Cholecystokinin and gut-brain signalling. Regul Pept. 2009;155:6–10. pmid:19345244
  17. 17. Li Y, Owyang C. Endogenous cholecystokinin stimulates pancreatic enzyme secretion via vagal afferent pathway in rats. Gastroenterology. 1994;107:525–531. pmid:8039628
  18. 18. Miller LJ, Desai AJ. Metabolic actions of the type 1 cholecystokinin receptor: Its potential as a therapeutic target. Trends Endocrinol Metab. 2016;27:609–619. pmid:27156041
  19. 19. Williams JA, Sans DM, Tashiro M, Schafer C, Bragado MJ, Dabrowski A. Cholecystokinin activates a variety of intracellular signal transduction mechanisms in rodent pancreatic acinar cells. Pharmacol Toxicol. 2002;91:297–303. pmid:12688372
  20. 20. Harikumar KG, Puri V, Singh RD, Hanada K, Pagano PE, Miller LJ. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem. 2005;280:2176–2185. pmid:15537636
  21. 21. Desai AJ, Dong M, Langlais BT, Dueck AC, Miller LJ. Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype. Am J Clin Nutr. 2017;106:447–456. pmid:28592602
  22. 22. Desai AJ, Miller LJ. Sensitivity of cholecystokinin receptors to membrane cholesterol content. Front Endocrinol. 2012;3:123. pmid:23087674
  23. 23. Kim K, Che T, Panova O., DiBerto JF, Lyu J, Krumm BE, et al. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell. 2020;182:1574–1588.e19. pmid:32946782
  24. 24. Hong C, Byrne NJ, Zamlynny B, Tummala S, Xiao L, Shipman JM, et al. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat Commun. 2021;12:815. pmid:33547286
  25. 25. Potter RM, Harikumar KG, Wu SV, Miller LJ. Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol. J Lipid Res. 2012;53:137–148. pmid:22021636
  26. 26. Harikumar KG, Potter RM, Patil A, Echeveste V, Miller LJ. Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol. Lipids. 2013;48:231–244. pmid:23306829
  27. 27. Maeda S, Qu Q, Robertson MJ, Skiniotis G, Kobilka BK. Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes. Science. 2019;364:553–557. pmid:31073061
  28. 28. Glukhova A, Thal DM, Nguyen AT, Vecchio EA, Jörg M, Scammells PJ, et al. Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity. Cell. 2017;168:867–877.e13. pmid:28235198
  29. 29. Draper-Joyce CJ, Khoshouei M, Thal DM, Liang YL, Nguyen ATN, Furness SGB, et al. Structure of the adenosine-bound human adenosine A1 receptor-Gi complex. Nature. 558:559–563. pmid:29925945
  30. 30. Gigoux V, Escrieut C, Fehrentz JA, Poirot S, Maigret B, Moroder L, et al. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin. J Biol Chem. 1999;274:20457–20464. pmid:10400673
  31. 31. Escrieut C, Gigoux V, Archer E, Verrier S, Maigret B, Behrendt R, et al. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process. J Biol Chem. 2002;277:7546–7555. pmid:11724786
  32. 32. Archer-Lahlou E, Tikhonova I, Escrieut C, Dufresne M, Seva C, Pradayrol L, et al. Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor. J Med Chem. 2005;48:180–191. pmid:15634012
  33. 33. Dong M, Lam PCH, Pinon DI, Abagyan R, Miller LJ. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. Biochemistry. 2009;48:5303–5312. pmid:19441839
  34. 34. Desai AJ, Harikumar HK, Miller LJ. A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment. J Biol Chem. 2014;289:18314–18326. pmid:24825903
  35. 35. Du Y, Duc NM, Rasmussen SGF, Hilger D, Kubiak X, Wang L, et al. Assembly of a GPCR-G Protein Complex. Cell. 2019;177:1232–1242.e11. pmid:31080064
  36. 36. Holst B, Nygaard R, Valentin-Hansen L, Bach A, Engelstoft MS, Petersen PS, et al. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J Biol Chem. 2010;285:3973–3985. pmid:19920139
  37. 37. Manglik A, Kruse AC. Structural Basis for G Protein-Coupled Receptor Activation. Biochemistry. 2017;56:5628–5634. pmid:28967738
  38. 38. Flock T, Ravarani C, Sun D, Venkatakrishnan AJ, Kayikci M, Tate CG, et al. A universal allosteric mechanism for Gα protein activation. Nature. 2015;524:173–179. pmid:26147082
  39. 39. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011;477:549–555. pmid:21772288
  40. 40. Liang YL, Belousoff MJ, Zhao P, Koole C, Fletcher MM, Truong TT, et al. Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation. Mol Cell. 2020;77:656–668.e5. pmid:32004469
  41. 41. Lin X, Li M, Wang N, Wu Y, Luo Z, Guo S, et al. Structural basis of ligand recognition and self-activation of orphan GPR52. Nature. 2020;579:152–157. pmid:32076264
  42. 42. Xiao P, Yan W, Gou L, Zhong YN, Kong L, Wu C, et al. Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes. Cell. 2021;184:943–956.e18. pmid:33571432
  43. 43. Zhuang Y, Xu P, Mao C, Wang L, Krumm B, Zhou XE, et al. Structural insights into the human D1 and D2 dopamine receptor signaling complexes. Cell. 2021;184:931–942.e18. pmid:33571431
  44. 44. Su M, Zhu L, Zhang Y, Paknejad N, Dey R, Huang J, et al. Structural Basis of the Activation of Heterotrimeric Gs-Protein by Isoproterenol-Bound beta(1)-Adrenergic Receptor. Mol Cell. 2020;80;59–71.e4. pmid:32818430
  45. 45. Koehl A, Hu H, Maeda S, Zhang Y, Qu Q, Paggi JM, et al. Structure of the μ-opioid receptor-Gi protein complex. Nature. 2018;558:547–552. pmid:29899455
  46. 46. Crilly SE, Ko W, Weinberg ZY, Puthenveedu MA. Conformational specificity of opioid receptors is determined by subcellular location irrespective of agonist. BioRxiv. 2021. pmid:34013886
  47. 47. Powers SP, Pinon DI, Miller LJ. Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. Int J Pept Protein Res. 1988;31:429–434. pmid:3410633
  48. 48. Stallaert W, van der Westhuizen ET, Schonegge AM, Plouffe B, Hogue M, Lukashova V, et al. Purinergic Receptor Transactivation by the beta2-Adrenergic Receptor Increases Intracellular Ca(2+) in Nonexcitable Cells. Mol Pharmacol. 2017;91:533–544. pmid:28280061
  49. 49. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, et al. TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods. 2012;9:1021–1029. pmid:22983457
  50. 50. Dong M, Xu X, Ball AM, Makhoul JA, Lam PC, Pinon DI, et al. Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping. FASEB J. 2012;26:5092–5105. pmid:22964305
  51. 51. Pontier SM, Percherancier Y, Galandrin S, Breit A, Gales C, Bouvier M. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem. 2008;283:24659–24672. pmid:18566454
  52. 52. Harikumar KG, Cawston EE, Lam PC, Patil A, Orry A, Henke BR, et al. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor. J Biol Chem. 2013;288:21082–21095. pmid:23754289
  53. 53. Harikumar KG, Pinon DI, Miller LJ. Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor. J Biol Chem. 2007;282:30363–30372. pmid:17726027
  54. 54. Liang YL, Khoshouei M, Glukhova A, Furness SGB, Zhao P, Clydesdale L, et al. Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. Nature. 2018;555:121–125. pmid:29466332
  55. 55. Kumar A, Plückthun A. In vivo assembly and large-scale purification of a GPCR—Galpha fusion with Gbetagamma, and characterization of the active complex. PLoS ONE. 2019;14:e0210131. pmid:30620756
  56. 56. Studier FW. Stable expression clones and auto-induction for protein production in E. coli. Methods Mol Biol. 2014;1091:17–32. pmid:24203322
  57. 57. Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9:674–693. pmid:24577359
  58. 58. Schorb M, Haberbosch I, Hagen WJH, Schwab Y, Mastronarde DN, Software tools for automated transmission electron microscopy. Nat Methods. 2019;16:471–477. pmid:31086343
  59. 59. Zheng SQ , Palovcak E., Armache J. P., Verba K. A., Cheng Y., DA Agard. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017;14;331–332. pmid:28250466
  60. 60. Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216–221. pmid:26278980
  61. 61. Wagner T, Merino F, Stabrin M, Moriya T, Antoni C, Apelbaum A, et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun Biol. 2019;2:218. pmid:31240256
  62. 62. Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA, cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290–296.
  63. 63. Ramlaul K, Palmer CM, Nakane T, Aylett CHS, Mitigating local over-fitting during single particle reconstruction with SIDESPLITTER. J Struct Biol. 2020;211:107545. pmid:32534144
  64. 64. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296–W303. pmid:29788355
  65. 65. Chan KY, Trabuco LG, Schreiner E, Schulten K. Cryo-electron microscopy modeling by the molecular dynamics flexible fitting method. Biopolymers. 2012;97:678–686. pmid:22696404
  66. 66. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486–501. pmid:20383002
  67. 67. Moriarty NW, Grosse-Kunstleve RW, Adams PD. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr D Biol Crystallogr. 2009;65:1074–1080. pmid:19770504
  68. 68. Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol. 2018;74:531–544. pmid:29872004
  69. 69. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70–82. pmid:32881101
  70. 70. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12–21. pmid:20057044
  71. 71. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372:774–797. pmid:17681537
  72. 72. Croll TI. ISOLDE: A Physically Realistic Environment for Model Building into Low-Resolution Electron-Density Maps. Acta Crystallographica Section D: Structural Biology. 74:519–530. pmid:29872003
  73. 73. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—A Visualization System for Exploratory Research and Analysis. J Comput Chem. 2004;25:1605–1612. pmid:15264254